Global Nocturia Market

Nocturia Comprehensive Study by Type (Nocturnal Polyuria, Bladder Storage Problems, Mixed Nocturia), Application (Hospitals, Clinics), Drug Form (Tablets, Nasal Spray), Types (Polyuria, Nocturnal Polyuria, Bladder Storage Problems, Mixed Nocturia), Causes (Urological Infection, Tumor of the Bladder, Diuretic Medications, Liver Infection, Diabetes, Others) Players and Region - Global Market Outlook to 2030

Nocturia Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 11.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Nocturia
Nocturia is a medical condition in which patients get a frequent urge to urinate while sleeping at night. It is particularly prevalent among the elderly who often find it difficult to sleep properly. It is a common condition experienced by both men and women with profound impact on patient’s health, quality of life, and economic condition. Especially among the elder patients, the lack of sleep often leads to nocturia, it is the most distressing symptoms in older men and women.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR11.3%


Companies are focusing on collaboration to develop new more effective products, mergers & acquisitions, expansions, investments. The product type segment of nocturia will be boosted by its higher response rate and increasing research activities for R&D leading to inorganic growth. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Allergan, Inc. (United States), Urigen Pharmaceuticals (United States), Ferring Holding SA (Switzerland), Glenmark Pharmaceuticals (India), Teva Pharmaceutical Industries Ltd. (Israel), Avadel Pharmaceuticals (Ireland), Vantia Therapeutics (United Kingdom) and Astellas Pharma Inc. (Japan) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Nocturia market by Type (Nocturnal Polyuria, Bladder Storage Problems and Mixed Nocturia), Application (Hospitals and Clinics) and Region.



On the basis of geography, the market of Nocturia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Form, the sub-segment i.e. Tablets will boost the Nocturia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Types, the sub-segment i.e. Polyuria will boost the Nocturia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Causes, the sub-segment i.e. Urological Infection will boost the Nocturia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising advancements in the drug delivery systems

Market Growth Drivers:
Rise in the prevalence of cardiovascular diseases

Challenges:
Lack of awareness about the treatments available

Restraints:
Undesired systemic effects of treatments

Opportunities:
Increasing investments in the healthcare sector in developing countries

Market Leaders and their expansionary development strategies
March 26, 2023: Allergan plc, a leading global pharmaceutical company announced it has completed the acquisition of Envy Medical, Inc., a privately held company with proprietary technology in skin resurfacing. The acquisition enhances Allergan's best-in-class Medical Aesthetics portfolio with the addition of Envy's Dermalinfusion, a non-surgical, non-invasive skin resurfacing system for the face and body.
April 05, 2021: Ferring Pharmaceuticals* and Rebiotix Inc. announced that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.


Key Target Audience
Suppliers of Pharmaceuticals, Wholesalers, Distributers and Retailers Pharmaceuticals, Healthcare Industry, Governmental Bodies and Academic and Government Research Institutes

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Nocturnal Polyuria
  • Bladder Storage Problems
  • Mixed Nocturia
By Application
  • Hospitals
  • Clinics
By Drug Form
  • Tablets
  • Nasal Spray

By Types
  • Polyuria
  • Nocturnal Polyuria
  • Bladder Storage Problems
  • Mixed Nocturia

By Causes
  • Urological Infection
  • Tumor of the Bladder
  • Diuretic Medications
  • Liver Infection
  • Diabetes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in the prevalence of cardiovascular diseases
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness about the treatments available
    • 3.4. Market Trends
      • 3.4.1. Rising advancements in the drug delivery systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
  • 5. Global Nocturia, by Type, Application, Drug Form, Types, Causes and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Nocturia (Price)
      • 5.2.1. Global Nocturia by: Type (Price)
  • 6. Nocturia: Manufacturers/Players Analysis
    • 6.1. Company Profile
      • 6.1.1. Allergan, Inc. (United States)
        • 6.1.1.1. Business Overview
        • 6.1.1.2. Products/Services Offerings
        • 6.1.1.3. Financial Analysis
        • 6.1.1.4. SWOT Analysis
      • 6.1.2. Urigen Pharmaceuticals (United States)
        • 6.1.2.1. Business Overview
        • 6.1.2.2. Products/Services Offerings
        • 6.1.2.3. Financial Analysis
        • 6.1.2.4. SWOT Analysis
      • 6.1.3. Ferring Holding SA (Switzerland)
        • 6.1.3.1. Business Overview
        • 6.1.3.2. Products/Services Offerings
        • 6.1.3.3. Financial Analysis
        • 6.1.3.4. SWOT Analysis
      • 6.1.4. Glenmark Pharmaceuticals (India)
        • 6.1.4.1. Business Overview
        • 6.1.4.2. Products/Services Offerings
        • 6.1.4.3. Financial Analysis
        • 6.1.4.4. SWOT Analysis
      • 6.1.5. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.1.5.1. Business Overview
        • 6.1.5.2. Products/Services Offerings
        • 6.1.5.3. Financial Analysis
        • 6.1.5.4. SWOT Analysis
      • 6.1.6. Avadel Pharmaceuticals (Ireland)
        • 6.1.6.1. Business Overview
        • 6.1.6.2. Products/Services Offerings
        • 6.1.6.3. Financial Analysis
        • 6.1.6.4. SWOT Analysis
      • 6.1.7. Vantia Therapeutics (United Kingdom)
        • 6.1.7.1. Business Overview
        • 6.1.7.2. Products/Services Offerings
        • 6.1.7.3. Financial Analysis
        • 6.1.7.4. SWOT Analysis
      • 6.1.8. Astellas Pharma Inc. (Japan)
        • 6.1.8.1. Business Overview
        • 6.1.8.2. Products/Services Offerings
        • 6.1.8.3. Financial Analysis
        • 6.1.8.4. SWOT Analysis
  • 7. Global Nocturia Sale, by Type, Application, Drug Form, Types, Causes and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Nocturia (Price)
      • 7.2.1. Global Nocturia by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nocturia: by Type(USD/Units)
  • Table 2. Company Basic Information, Sales Area and Its Competitors
  • Table 3. Company Basic Information, Sales Area and Its Competitors
  • Table 4. Company Basic Information, Sales Area and Its Competitors
  • Table 5. Company Basic Information, Sales Area and Its Competitors
  • Table 6. Company Basic Information, Sales Area and Its Competitors
  • Table 7. Company Basic Information, Sales Area and Its Competitors
  • Table 8. Company Basic Information, Sales Area and Its Competitors
  • Table 9. Company Basic Information, Sales Area and Its Competitors
  • Table 10. Nocturia: by Type(USD/Units)
  • Table 11. Research Programs/Design for This Report
  • Table 12. Key Data Information from Secondary Sources
  • Table 13. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nocturia: by Type USD/Units (2018-2023)
  • Figure 5. Allergan, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 6. Allergan, Inc. (United States) Revenue: by Geography 2023
  • Figure 7. Urigen Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 8. Urigen Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 9. Ferring Holding SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 10. Ferring Holding SA (Switzerland) Revenue: by Geography 2023
  • Figure 11. Glenmark Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 12. Glenmark Pharmaceuticals (India) Revenue: by Geography 2023
  • Figure 13. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 14. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 15. Avadel Pharmaceuticals (Ireland) Revenue, Net Income and Gross profit
  • Figure 16. Avadel Pharmaceuticals (Ireland) Revenue: by Geography 2023
  • Figure 17. Vantia Therapeutics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Vantia Therapeutics (United Kingdom) Revenue: by Geography 2023
  • Figure 19. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Astellas Pharma Inc. (Japan) Revenue: by Geography 2023
  • Figure 21. Global Nocturia: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Allergan, Inc. (United States)
  • Urigen Pharmaceuticals (United States)
  • Ferring Holding SA (Switzerland)
  • Glenmark Pharmaceuticals (India)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Avadel Pharmaceuticals (Ireland)
  • Vantia Therapeutics (United Kingdom)
  • Astellas Pharma Inc. (Japan)
Select User Access Type

Key Highlights of Report


Apr 2024 232 Pages 84 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Nocturia Market Quantitative research analysis
Global Nocturia Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Allergan, Inc. (United States), Urigen Pharmaceuticals (United States), Ferring Holding SA (Switzerland), Glenmark Pharmaceuticals (India), Teva Pharmaceutical Industries Ltd. (Israel), Avadel Pharmaceuticals (Ireland), Vantia Therapeutics (United Kingdom) and Astellas Pharma Inc. (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising advancements in the drug delivery systems" is seen as one of major influencing trends for Nocturia Market during projected period 2023-2030.
The Nocturia market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Nocturia Market Report?

Have a Query? Click Here

Other Related Reports

Shoulder Labrum Repair Comprehensive Study by Type (PLA Resorbable Suture Anchor, Biocomposite Suture Anchor, PEEK Suture Anchor, Metal Suture Anchor, All-Suture Anchor), Application (Rotator Cuff Te...
$ 3650
Breast Biopsy Comprehensive Study by Type (Core Needle Biopsy (CNB), Vacuum-Assisted Biopsy (VAB), Fine Needle Aspiration Biopsy (FNAB)), Application (Hospitals, Clinics, Diagnostic Centers, Others),...
$ 3750
Antiretroviral Therapy Comprehensive Study by Route of Administration (Oral, Parenteral), Class (Nucleoside Reverse Transcriptase Inhibitors, HIV Protease Inhibitors, Non-nucleoside Reverse Transcrip...
$ 3650
CD Antigen Cancer Therapy Comprehensive Study by Type (Monoclonal Antibodies, Antibody-Drug-Conjugates, Tri-Functional & Bi-Specific T-Cell Engager Antibodies, Other), Application (Hospitals, Homecar...
$ 3750
Neuroprotection Comprehensive Study by Type (Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic...
$ 3750
Human Rabies Immunoglobulin Comprehensive Study by Side effects (Pain, Fever, Headache, Others), Rabies (Encephalitic, Paralytic), Immunoglobulin (IgG, IgM, IgA, IgD, IgE) Players and Region - Globa...
$ 3500